Trehalose Attenuates the Gait Ataxia and Gliosis of Spinocerebellar Ataxia Type 17 Mice

Zhi Zhong Chen, Chien Ming Wang, Guan Chiun Lee, Ho Chiang Hsu, Tzu Ling Wu, Chia Wei Lin, Chih Kang Ma, Guey Jen Lee-Chen, Hei Jen Huang, Hsiu Mei Hsieh-Li

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Spinocerebellar ataxia type 17 (SCA17) is caused by CAG/CAA repeat expansion on the gene encoding a general transcription factor, TATA-box-binding protein (TBP). The CAG repeat expansion leads to the reduced solubility of polyglutamine TBP and induces aggregate formation. The TBP aggregation, mostly present in the cell nuclei, is distinct from that in most other neurodegenerative diseases, in which the aggregation is formed in cytosol or extracellular compartments. Trehalose is a disaccharide issued by the Food and Drug Administration with a Generally Recognized As Safe status. Lines of evidence suggest trehalose could prevent protein aggregate formation in several neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease. In this study, we evaluated the therapeutic potential of trehalose on SCA17 using cerebellar primary and organotypic culture systems and a mouse model. Our results showed that TBP nuclear aggregation was significantly decreased in both the primary and slice cultures. Trehalose (4 %) was further supplied in the drinking water of SCA17 transgenic mice. We found both the gait behavior in the footprint analysis and motor coordination in the rotarod task were significantly improved in the trehalose-treated SCA17 mice. The cerebellar weight was increased and the astrocyte gliosis was reduced in SCA17 mice after trehalose treatment. These data suggest that trehalose could be a potential nontoxic treatment for SCA17.

Original languageEnglish
Pages (from-to)800-810
Number of pages11
JournalNeurochemical Research
Volume40
Issue number4
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Gait Ataxia
Trehalose
Gliosis
TATA-Box Binding Protein
Neurodegenerative diseases
Agglomeration
Neurodegenerative Diseases
General Transcription Factors
Gene encoding
Disaccharides
United States Food and Drug Administration
Spinocerebellar Ataxia 17
Cell Nucleus
Gait
Astrocytes
Drinking Water
Cytosol
Solubility
Transgenic Mice
Cells

Keywords

  • Intranuclear aggregation
  • Spinocerebellar ataxia
  • TBP
  • Trehalose

ASJC Scopus subject areas

  • Biochemistry
  • Cellular and Molecular Neuroscience

Cite this

Trehalose Attenuates the Gait Ataxia and Gliosis of Spinocerebellar Ataxia Type 17 Mice. / Chen, Zhi Zhong; Wang, Chien Ming; Lee, Guan Chiun; Hsu, Ho Chiang; Wu, Tzu Ling; Lin, Chia Wei; Ma, Chih Kang; Lee-Chen, Guey Jen; Huang, Hei Jen; Hsieh-Li, Hsiu Mei.

In: Neurochemical Research, Vol. 40, No. 4, 01.01.2015, p. 800-810.

Research output: Contribution to journalArticle

Chen, Zhi Zhong ; Wang, Chien Ming ; Lee, Guan Chiun ; Hsu, Ho Chiang ; Wu, Tzu Ling ; Lin, Chia Wei ; Ma, Chih Kang ; Lee-Chen, Guey Jen ; Huang, Hei Jen ; Hsieh-Li, Hsiu Mei. / Trehalose Attenuates the Gait Ataxia and Gliosis of Spinocerebellar Ataxia Type 17 Mice. In: Neurochemical Research. 2015 ; Vol. 40, No. 4. pp. 800-810.
@article{1db26d42b8134afb85476b70606f2293,
title = "Trehalose Attenuates the Gait Ataxia and Gliosis of Spinocerebellar Ataxia Type 17 Mice",
abstract = "Spinocerebellar ataxia type 17 (SCA17) is caused by CAG/CAA repeat expansion on the gene encoding a general transcription factor, TATA-box-binding protein (TBP). The CAG repeat expansion leads to the reduced solubility of polyglutamine TBP and induces aggregate formation. The TBP aggregation, mostly present in the cell nuclei, is distinct from that in most other neurodegenerative diseases, in which the aggregation is formed in cytosol or extracellular compartments. Trehalose is a disaccharide issued by the Food and Drug Administration with a Generally Recognized As Safe status. Lines of evidence suggest trehalose could prevent protein aggregate formation in several neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease. In this study, we evaluated the therapeutic potential of trehalose on SCA17 using cerebellar primary and organotypic culture systems and a mouse model. Our results showed that TBP nuclear aggregation was significantly decreased in both the primary and slice cultures. Trehalose (4 {\%}) was further supplied in the drinking water of SCA17 transgenic mice. We found both the gait behavior in the footprint analysis and motor coordination in the rotarod task were significantly improved in the trehalose-treated SCA17 mice. The cerebellar weight was increased and the astrocyte gliosis was reduced in SCA17 mice after trehalose treatment. These data suggest that trehalose could be a potential nontoxic treatment for SCA17.",
keywords = "Intranuclear aggregation, Spinocerebellar ataxia, TBP, Trehalose",
author = "Chen, {Zhi Zhong} and Wang, {Chien Ming} and Lee, {Guan Chiun} and Hsu, {Ho Chiang} and Wu, {Tzu Ling} and Lin, {Chia Wei} and Ma, {Chih Kang} and Lee-Chen, {Guey Jen} and Huang, {Hei Jen} and Hsieh-Li, {Hsiu Mei}",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/s11064-015-1530-4",
language = "English",
volume = "40",
pages = "800--810",
journal = "Neurochemical Research",
issn = "0364-3190",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Trehalose Attenuates the Gait Ataxia and Gliosis of Spinocerebellar Ataxia Type 17 Mice

AU - Chen, Zhi Zhong

AU - Wang, Chien Ming

AU - Lee, Guan Chiun

AU - Hsu, Ho Chiang

AU - Wu, Tzu Ling

AU - Lin, Chia Wei

AU - Ma, Chih Kang

AU - Lee-Chen, Guey Jen

AU - Huang, Hei Jen

AU - Hsieh-Li, Hsiu Mei

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Spinocerebellar ataxia type 17 (SCA17) is caused by CAG/CAA repeat expansion on the gene encoding a general transcription factor, TATA-box-binding protein (TBP). The CAG repeat expansion leads to the reduced solubility of polyglutamine TBP and induces aggregate formation. The TBP aggregation, mostly present in the cell nuclei, is distinct from that in most other neurodegenerative diseases, in which the aggregation is formed in cytosol or extracellular compartments. Trehalose is a disaccharide issued by the Food and Drug Administration with a Generally Recognized As Safe status. Lines of evidence suggest trehalose could prevent protein aggregate formation in several neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease. In this study, we evaluated the therapeutic potential of trehalose on SCA17 using cerebellar primary and organotypic culture systems and a mouse model. Our results showed that TBP nuclear aggregation was significantly decreased in both the primary and slice cultures. Trehalose (4 %) was further supplied in the drinking water of SCA17 transgenic mice. We found both the gait behavior in the footprint analysis and motor coordination in the rotarod task were significantly improved in the trehalose-treated SCA17 mice. The cerebellar weight was increased and the astrocyte gliosis was reduced in SCA17 mice after trehalose treatment. These data suggest that trehalose could be a potential nontoxic treatment for SCA17.

AB - Spinocerebellar ataxia type 17 (SCA17) is caused by CAG/CAA repeat expansion on the gene encoding a general transcription factor, TATA-box-binding protein (TBP). The CAG repeat expansion leads to the reduced solubility of polyglutamine TBP and induces aggregate formation. The TBP aggregation, mostly present in the cell nuclei, is distinct from that in most other neurodegenerative diseases, in which the aggregation is formed in cytosol or extracellular compartments. Trehalose is a disaccharide issued by the Food and Drug Administration with a Generally Recognized As Safe status. Lines of evidence suggest trehalose could prevent protein aggregate formation in several neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease. In this study, we evaluated the therapeutic potential of trehalose on SCA17 using cerebellar primary and organotypic culture systems and a mouse model. Our results showed that TBP nuclear aggregation was significantly decreased in both the primary and slice cultures. Trehalose (4 %) was further supplied in the drinking water of SCA17 transgenic mice. We found both the gait behavior in the footprint analysis and motor coordination in the rotarod task were significantly improved in the trehalose-treated SCA17 mice. The cerebellar weight was increased and the astrocyte gliosis was reduced in SCA17 mice after trehalose treatment. These data suggest that trehalose could be a potential nontoxic treatment for SCA17.

KW - Intranuclear aggregation

KW - Spinocerebellar ataxia

KW - TBP

KW - Trehalose

UR - http://www.scopus.com/inward/record.url?scp=84939939570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939939570&partnerID=8YFLogxK

U2 - 10.1007/s11064-015-1530-4

DO - 10.1007/s11064-015-1530-4

M3 - Article

C2 - 25672822

AN - SCOPUS:84939939570

VL - 40

SP - 800

EP - 810

JO - Neurochemical Research

JF - Neurochemical Research

SN - 0364-3190

IS - 4

ER -